By UGA Biopharma…
UGA Biopharma to debut at digital Bioprocessing Summit Europe
Hennigsdorf, Germany: Leading-edge contract developer of cell lines expressing biologics and biosimilars, UGA Biopharma GmbH, will make its debut at the upcoming annual Bioprocessing Summit Europe conference, now repurposed as a virtual online event in response to the COVID-19 pandemic.
Fast-track cell line development
The UGA team led by Business Development Manager, Dr. Marcel Nowak, will use the conference’s online networking sessions to present their fast-track biologic contract cell line development services that can bring therapeutic antibodies, bispecific antibodies, fusion proteins, enzymes and hormones into full production, including USP and DSP strategies.
“We are looking forward to attending this valuable event that will give us a great platform to get into conversations about high performance cell lines with titers from 4 to 7 g/L for production of new biologics, together with fast timelines, high biosimilarity, traceability and our superb track record,” said Dr. Nowak.
About UGA Biopharma
UGA Biopharma GmbH is an experienced contract developer of biologics and biosimilars with the capabilities to handle all necessary steps from cell line development and bioprocess development to the development of purification strategies and appropriate analytics.
The company supplies its customers in Germany and abroad from its headquarter in Hennigsdorf, near Berlin. Several clients have used UGA products in clinical trials or in products that have received market authorization.
UGA Biopharma GmbH CRO activities are centered on cell line development for biologics and biosimilars, specializing in the development of stable expressing CHO cell lines and cell media for the production of biologics and biosimilars for biopharmaceutical companies. Typical clients are biopharma manufacturers, research institutions (like universities and research institutes) as well as start-ups and other CROs that need to outsource CLD, upstream, and/or downstream processing.
UGA’s mission is to fulfill customer requests, recognizing industry needs for high titer, high quality and fast delivery timelines, along with robust CHO cell lines. To this end, UGA can deliver cell lines, reaching titers from 4 to 7 g/L, within four months of receiving the originator sequence.
UGA has also developed its proprietary First CHOice® cell culture media and feeds platform to boost the productivity of cell lines. Furthermore, UGA Biopharma GmbH offers ready-to-use biosimilar cell lines, which allow clients interested in biosimilar development fast track access to a highly biosimilar cell line.
Further information at: www.ugabiopharma.com
About Bioprocessing Summit Europe 2020
Founded in 2017, the annual European Bioprocessing Summit focuses on practical solutions for current bioprocess business challenges.
The conference covers Upstream (USP) and Downstream (DSP) Processing, Cell & Gene Therapy and Analytical & Formulation activities.
The 3rd Bioprocessing Europe Summit was originally a three-day event running from July 21 to July 23 at the Crowne Plaza and nearby Fira Center in Barcelona. In response to the COVID-19 pandemic, it has now been converted to a virtual event hosted online between the same dates.
Organizers Cambridge Health Institute (CHI) say the digital event will feature online sessions, networking, exhibits and posters, run in “real time” between 0800 and 1700 hrs CET (GMT+2) on all three days of the conference. Most sessions will be available to view on demand after the virtual meeting has ended.
Further information at: https://www.bioprocessingeurope.com
Click on UGA Biosimilar Development for detailed service information.